Podcast Episodes
Back to Search
Pharmaceutical Executive Daily: Conflict in Middle East Disrupts Pharma Supply Chains
In today's Pharmaceutical Executive Daily, ongoing conflict in the Middle East is straining pharmaceutical supply routes to the Gulf region, Sentynl …
2 months ago
Pharmaceutical Executive Daily: FDA Expands Approval for Arexvy
In today's Pharmaceutical Executive Daily, a new West Health-Gallup survey finds that more than 82 million Americans have cut back on daily expenses …
2 months, 1 week ago
Pharmaceutical Executive Daily: Senate Democrats Seeking Information on MFN Pharma Deals
2 months, 1 week ago
Moving CAR-T Beyond Oncology
Vincent Hennemand discusses using these types of therapies to develop treatments for autoimmune conditions.
2 months, 1 week ago
Pharmaceutical Executive Daily: FDA's New Guidance for Biosimilar Development
In today's Pharmaceutical Executive Daily, the FDA issues new draft guidance aimed at reducing the cost and complexity of biosimilar development, Nov…
2 months, 1 week ago
Pharmaceutical Executive Daily: FDA Expands Approval of Leucovorin
In today's Pharmaceutical Executive Daily, the FDA approves leucovorin as the first-ever treatment for an ultra-rare genetic condition called cerebra…
2 months, 1 week ago
Pharmaceutical Executive Daily: Vinay Prasad Set to Leave CBER for Second Time
In today’s Pharmaceutical Executive Daily, Vinay Prasad exits the FDA’s Center for Biologics Evaluation and Research for the second time in under a y…
2 months, 1 week ago
Pharmaceutical Executive Daily: Cognito Therapeutics and Nexcure Secure Financing Rounds
In today’s Pharmaceutical Executive Daily, Cognito Therapeutics and Nexcure secure new financing rounds to advance their pipelines, artificial intell…
2 months, 2 weeks ago
Pharmaceutical Executive Daily: Pharma Industry's AI Adoption
In today’s Pharmaceutical Executive Daily, Antengene and UCB enter a billion-dollar global licensing agreement for a bispecific T-cell engager, Teva …
2 months, 2 weeks ago
The Ongoing Impact of MFN Pricing
Alice Valdur Curan discusses how the industry continues to strategize around this complicated order.
2 months, 2 weeks ago